482 related articles for article (PubMed ID: 25640268)
1. Lipid regulation of the ABCB1 and ABCG2 multidrug transporters.
Hegedüs C; Telbisz Á; Hegedűs T; Sarkadi B; Özvegy-Laczka C
Adv Cancer Res; 2015; 125():97-137. PubMed ID: 25640268
[TBL] [Abstract][Full Text] [Related]
2. Novel understanding of ABC transporters ABCB1/MDR/P-glycoprotein, ABCC2/MRP2, and ABCG2/BCRP in colorectal pathophysiology.
Andersen V; Svenningsen K; Knudsen LA; Hansen AK; Holmskov U; Stensballe A; Vogel U
World J Gastroenterol; 2015 Nov; 21(41):11862-76. PubMed ID: 26557010
[TBL] [Abstract][Full Text] [Related]
3. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
Hu J; Zhang X; Wang F; Wang X; Yang K; Xu M; To KK; Li Q; Fu L
Oncotarget; 2015 Dec; 6(42):44643-59. PubMed ID: 26556876
[TBL] [Abstract][Full Text] [Related]
4. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
[TBL] [Abstract][Full Text] [Related]
5. ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis.
Cotte S; von Ahsen N; Kruse N; Huber B; Winkelmann A; Zettl UK; Starck M; König N; Tellez N; Dörr J; Paul F; Zipp F; Lühder F; Koepsell H; Pannek H; Montalban X; Gold R; Chan A
Brain; 2009 Sep; 132(Pt 9):2517-30. PubMed ID: 19605531
[TBL] [Abstract][Full Text] [Related]
6. LRIG1, human EGFR inhibitor, reverses multidrug resistance through modulation of ABCB1 and ABCG2.
Liu B; Guo Z; Dong H; Daofeng T; Cai Q; Ji B; Zhang S; Wu L; Wang J; Wang L; Zhu X; Liu Y; Chen Q
Brain Res; 2015 Jun; 1611():93-100. PubMed ID: 25801120
[TBL] [Abstract][Full Text] [Related]
7. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense.
Leslie EM; Deeley RG; Cole SP
Toxicol Appl Pharmacol; 2005 May; 204(3):216-37. PubMed ID: 15845415
[TBL] [Abstract][Full Text] [Related]
8. Promoter methylation patterns of ABCB1, ABCC1 and ABCG2 in human cancer cell lines, multidrug-resistant cell models and tumor, tumor-adjacent and tumor-distant tissues from breast cancer patients.
Spitzwieser M; Pirker C; Koblmüller B; Pfeiler G; Hacker S; Berger W; Heffeter P; Cichna-Markl M
Oncotarget; 2016 Nov; 7(45):73347-73369. PubMed ID: 27689338
[TBL] [Abstract][Full Text] [Related]
9. Grid-independent Descriptors (GRIND) Analysis and SAR Guided Molecular Docking Studies to Probe Selectivity Profiles of Inhibitors of Multidrug Resistance Transporters ABCB1 and ABCG2.
Shafi T; Jabeen I
Curr Cancer Drug Targets; 2017; 17(2):177-190. PubMed ID: 27585695
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2.
Lepper ER; Nooter K; Verweij J; Acharya MR; Figg WD; Sparreboom A
Pharmacogenomics; 2005 Mar; 6(2):115-38. PubMed ID: 15882131
[TBL] [Abstract][Full Text] [Related]
11. Vatalanib sensitizes ABCB1 and ABCG2-overexpressing multidrug resistant colon cancer cells to chemotherapy under hypoxia.
To KK; Poon DC; Wei Y; Wang F; Lin G; Fu LW
Biochem Pharmacol; 2015 Sep; 97(1):27-37. PubMed ID: 26206183
[TBL] [Abstract][Full Text] [Related]
12. Multidrug resistance gene expression and ABCB1 SNPs in plasma cell myeloma.
Drain S; Flannely L; Drake MB; Kettle P; Orr N; Bjourson AJ; Catherwood MA; Alexander HD
Leuk Res; 2011 Nov; 35(11):1457-63. PubMed ID: 21705081
[TBL] [Abstract][Full Text] [Related]
13. Application of fluorescent dye substrates for functional characterization of ABC multidrug transporters at a single cell level.
Nerada Z; Hegyi Z; Szepesi Á; Tóth S; Hegedüs C; Várady G; Matula Z; Homolya L; Sarkadi B; Telbisz Á
Cytometry A; 2016 Sep; 89(9):826-34. PubMed ID: 27602881
[TBL] [Abstract][Full Text] [Related]
14. Trametinib modulates cancer multidrug resistance by targeting ABCB1 transporter.
Qiu JG; Zhang YJ; Li Y; Zhao JM; Zhang WJ; Jiang QW; Mei XL; Xue YQ; Qin WM; Yang Y; Zheng DW; Chen Y; Wei MN; Shi Z
Oncotarget; 2015 Jun; 6(17):15494-509. PubMed ID: 25915534
[TBL] [Abstract][Full Text] [Related]
15. Allocrite Sensing and Binding by the Breast Cancer Resistance Protein (ABCG2) and P-Glycoprotein (ABCB1).
Xu Y; Egido E; Li-Blatter X; Müller R; Merino G; Bernèche S; Seelig A
Biochemistry; 2015 Oct; 54(40):6195-206. PubMed ID: 26381710
[TBL] [Abstract][Full Text] [Related]
16. Molecular response to imatinib & its correlation with mRNA expression levels of imatinib influx & efflux transporters in patients with chronic myeloid leukaemia in chronic phase.
Malhotra H; Sharma P; Malhotra B; Bhargava S; Jasuja S; Kumar M
Indian J Med Res; 2015 Aug; 142(2):175-82. PubMed ID: 26354214
[TBL] [Abstract][Full Text] [Related]
17. Effect of oxygen on multidrug resistance in the first trimester human placenta.
Lye P; Bloise E; Dunk C; Javam M; Gibb W; Lye SJ; Matthews SG
Placenta; 2013 Sep; 34(9):817-23. PubMed ID: 23790363
[TBL] [Abstract][Full Text] [Related]
18. Effect of abemaciclib (LY2835219) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
Wu T; Chen Z; To KKW; Fang X; Wang F; Cheng B; Fu L
Biochem Pharmacol; 2017 Jan; 124():29-42. PubMed ID: 27816545
[TBL] [Abstract][Full Text] [Related]
19. Predicting Activators and Inhibitors of the Breast Cancer Resistance Protein (ABCG2) and P-Glycoprotein (ABCB1) Based on Mechanistic Considerations.
Egido E; Müller R; Li-Blatter X; Merino G; Seelig A
Mol Pharm; 2015 Nov; 12(11):4026-37. PubMed ID: 26372856
[TBL] [Abstract][Full Text] [Related]
20. Expression and activity of ABCG2, but not ABCB1 or OATP1B1, are associated with cholesterol levels: evidence from in vitro and in vivo experiments.
To KK; Hu M; Tomlinson B
Pharmacogenomics; 2014 Jun; 15(8):1091-104. PubMed ID: 25084202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]